By mimicking the action of GLP-1, Semaglutide curbs the desire to eat, aiding in calorie reduction and weight management
Headline results from ESSENCE, which formed the basis of that 2025 approval, included: About 63 percent of semaglutide-treated patients reached resolution of steatohepatitis without worsening of liver fibrosis at 72 weeks Approximately 37 percent showed measurable improvement in liver fibrosis (the scarring that drives long-term liver damage) Mean body-weight reduction reached roughly 10 percent over 72 weeks of weekly subcutaneous semaglutide Gastrointestinal symptoms (nausea, early fullness, mild diarrhea) were the most common side effects, generally manageable with gradual dose escalation Source: FDA Wegovy approval materials, 2025 (FDA Drugs) The SLIM LIVER Trial and What It Found in People with HIV The ESSENCE numbers above come from the general MASH population, not specifically from people living with HIV
If it is consistently dark despite drinking adequate fluids, you likely need more electrolytes, not more water
Useful Links : Meet the once-daily Wegovy Wegovy.com Diabetes drugs and weight loss Mayo Clinic How to Get a Mounjaro Prescription Online: Safe Weight Loss Shots Near You What Is The Most Successful Medication For Weight Loss
